Yes. This recommendation or, again, lack of a recommendation, is about an entire class of medications. This type of wording in medical recommendations is common when the jury is still out. I am an investor and agree that there isn’t enough evidence to blanket recommend GM-CSF inhibitors. That said, in my opinion, there is enough evidence specifically for a lenzilumab EUA, but that is a different question than a full recommendation of a class of drugs. You are conflating the two and also, additionally, taking the NIH’s specific “non” recommendation as a recommendation.
News 
Market Data 
Discover 
